Clinical effectiveness of new generation antipsychotics in adolescent patients

European Neuropsychopharmacology

Volumn 14, Issue SUPPL. 4, 2004, Pages

  Arango, Celso ^a   Parellada, Mara ^a   Moreno, Dolores Maria ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Adolescents; Antipsychotics; Clinical effectiveness; Psychosis; Quetiapine

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENCE; AGE DISTRIBUTION; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; MANIA; MENSTRUAL IRREGULARITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WEIGHT GAIN; WELLBEING;

EID: 9644257442     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2004.08.006     Document Type: Article

References (62)

1. E.J. Aguilar, M.S. Keshavan, M.D. Martínez-Quiles, J. Hernández, M. Gómez-Beneyto, and N.R. Schooler Predictors of acute dystonia in first-episode psychotic patients Am. J. Psychiatry 151 1994 1819 1821
2. D.B. Allison, J.A. Mackell, and D.D. McDonnell The impact of weight gain on quality of life among persons with schizophrenia Psychiatr. Serv. 54 2003 565 567
3. J.L. Armenteros, A.H. Whitaker, M. Welikson, D.J. Stedge, and J. Gorman Risperidone in adolescents with schizophrenia: an open pilot study J. Am. Acad. Child Adolesc. Psych. 36 1997 694 700
4. M. Atmaca, M. Kuloglu, E. Tezcan, H. Canatan, and O. Gecici Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol Arch. Med. Res. 33 2002 562 565
5. G. Bartkó, H. Váradi, L. Simon, E. Linka, T. Tüske, T. Szabó, and J. Sántha Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia Int. J. Psychiatry Clin. Pract. 6 2002 9 14
6. S. Beratis, J. Gabriel, and S. Hoidas Age at onset in subtypes of schizophrenic disorders Schizophr. Bull. 20 1994 287 296
7. J. Bobes, M.P. Garcia-Portilla, P.A. Saiz, M.-T. Bascaran, M. Bousono, and C. Arango High degree of tolerability for monotherapy with high doses of quetiapine: a case report J. Clin. Psychiatry 63 2002 1048 1049
8. K.E. Bryden, N.J. Carrey, and S.P. Kutcher Update and recommendations for the use of antipsychotics in early-onset psychoses J. Child Adolesc. Psychopharmacol. 11 2001 113 130
9. K.E. Bryden, D.M. Gardner, and L.C. Kopala First episode psychosis: early intervention strategies with second-generation antipsychotic medications Int. J. Clin. Pract. 57 2003 513 518
10. B. Bühler, M. Hambrecht, W. Löffler, W. an der Heiden, and H. Häfner Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes Schizophr. Res. 54 2002 243 251
11. J.K. Buitelaar Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior J. Child Adolesc. Psychopharmacol. 10 2000 19 26
12. K.N.R. Chengappa, H. Parepally, J.S. Brar, J. Mullen, A. Shilling, and J.M. Goldstein A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study Can. J. Psychiatry 48 2003 187 194
13. L. Citrome, and J. Volavka Optimal dosing of atypical antipsychotics in adults: a review of the current evidence Harv. Rev. Psychiatry 10 2002 280 291
14. M.P. DelBello, M.L. Schwiers, H.L. Rosenberg, and S.M. Strakowski A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania J. Am. Acad. Child Adolesc. Psych. 41 2002 1216 1223
15. R.A. Emsley, J. Raniwalla, P.J. Bailey, A.M. Jones on behalf of the PRIZE Study Group A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment Int. Clin. Psychopharmacol. 15 2000 121 131
16. R.L. Findling Paediatric psychopharmacology: closing the gap between science and practice Expert Opin. Pharmacother. 2 2001 523 525
17. R.L. Findling, N.K. McNamara, E.A. Youngstrom, L.A. Branicky, C.A. Demeter, and S.C. Schulz A prospective, open-label trial of olanzapine in adolescents with schizophrenia J. Am. Acad. Child Adolesc. Psych. 42 2003 170 175
18. J.A. Frazier, L.G. Cohen, L. Jacobsen, D. Grothe, J. Flood, R.J. Baldessarini, S. Piscitelli, G.S. Kim, and J.L. Rapoport Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia J. Clin. Psychopharmacol. 23 2003 87 91
19. P.J. Goodnick, L. Rodriguez, and O. Santana Antipsychotics: impact on prolactin levels Expert Opin. Pharmacother. 3 2002 1381 1391
20. D. Gothelf, A. Apter, J. Reidman, A. Brand-Gothelf, Y. Bloch, G. Gal, L. Kikinzon, S. Tyano, R. Weizman, and G. Ratzoni Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia J. Neural Transm. 110 2003 545 560
21. S. Grcevich Comparative side effects of atypical antipsychotics in children and adolescents Schizophr. Res. 49 2001 284 (suppl)
22. S.J. Grcevich, R.L. Findling, W.A. Rowane, L. Friedman, and S.C. Schulz Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study J. Child Adolesc. Psychopharmacol. 6 1996 251 257
23. D.R. Grothe, K.A. Calis, L. Jacobsen, S. Kumra, C.L. DeVane, J.L. Rapoport, R.F. Bergstrom, and D.L. Kurtz Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia J. Clin. Psychopharmacol. 20 2000 220 225
24. J.S.E. Hellewell, A.H. Kalali, S.J. Langham, J. McKellar, and A.G. Awad Patient satisfaction and acceptability of long-term treatment with quetiapine Int. J. Psychiatry Clin. Pract. 3 1999 105 113
25. J.M. Kane, M. Eerdekens, J.P. Lindenmayer, S.J. Keith, M. Lesem, and K. Karcher Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic Am. J. Psychiatry 160 2003 1125 1132
26. S. Kasper, and F. Müller-Spahn Review of quetiapine and its clinical applications in schizophrenia Expert Opin. Pharmacother. 1 2000 783 801
27. D.L. Kelly, R.R. Conley, R.C. Love, D.S. Horn, and C.M. Ushchak Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months J. Child Adolesc. Psychopharmacol. 8 1998 151 159
28. C.M. Kodjo, and J.D. Klein Prevention and risk of adolescent substance abuse. The role of adolescents, families, and communities Pediatr. Clin. North Am. 49 2002 257 268
29. R.A. Kowatch, and M.P. DelBello The use of mood stabilizers and atypical antipsychotics in children and adolescents with bipolar disorders CNS Spectr. 8 2003 273 280
30. S. Kumra, J.A. Frazier, L.K. Jacobsen, K. McKenna, C.T. Gordon, M.C. Lenane, S.D. Hamburger, A.K. Smith, K.E. Albus, J. Alaghband-Rad, and J.L. Rapoport Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison Arch. Gen. Psychiatry 53 1996 1090 1097
31. S. Kumra, L.K. Jacobsen, M. Lenane, B.I. Karp, J.A. Frazier, A.K. Smith, J. Bedwell, P. Lee, C.J. Malanga, S. Hamburger, and J.L. Rapoport Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents J. Am. Acad. Child Adolesc. Psych. 37 1998 377 385
32. P. Lalonde Evaluating antipsychotic medications: predictors of clinical effectiveness Can. J. Psychiatry 48 Suppl 1 2003 1S 12S
33. R. Lewis Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms Can. J. Psychiatry 43 1998 596 604
34. J. Lieberman, D. Jody, S. Geisler, J. Alvir, A. Loebel, S. Szymanski, M. Woerner, and M. Borenstein Time course and biologic correlates of treatment response in first-episode schizophrenia Arch. Gen. Psychiatry 50 1993 369 376
35. J.A. Lieberman, D. Perkins, A. Belger, M. Chakos, F. Jarskog, K. Boteva, and J. Gilmore The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches Biol. Psychiatry 50 2001 884 897
36. J.A. Lieberman, G. Tollefson, M. Tohen, A.I. Green, R.E. Gur, R. Kahn, J. McEvoy, D. Perkins, T. Sharma, R. Zipursky, H. Wei, R.M. Hamer HGDH Study Group Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol Am. J. Psychiatry 160 2003 1396 1404
37. B.J. McConville, L.A. Arvanitis, P.T. Thyrum, C. Yeh, L.A. Wilkinson, R.O. Chaney, K.D. Foster, M.T. Sorter, L.M. Friedman, K.L. Brown, and J.E. Heubi Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders J. Clin. Psychiatry 61 2000 252 260
38. B. McConville, L. Carrero, D. Sweitzer, L. Potter, R. Chaney, K. Foster, M. Sorter, L. Friedman, and K. Browne Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial J. Child Adolesc. Psychopharmacol. 13 2003 75 82
39. R.J. Merritt Obesity Curr. Probl. Pediatr. 12 1982 1 58
40. D.J. Miklowitz, M.J. Goldstein, K.H. Nuechterlein, K.S. Snyder, and J. Mintz Family factors and the course of bipolar affective disorder Arch. Gen. Psychiatry 45 1988 225 231
41. MIMS Central nervous system. Antipsychotics. Zyprexa Monthly Index of Medical Specialities 2004 Haymarket Medical Publishers London 97
42. N.P. Nair The Risperidone Study Group Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia J. Clin. Psychopharmacol. 18 1998 103 110
43. National Institutes of Health Clinical guidelines on the identification, evaluation and treatment of over weight and obesity in adults: the evidence report Obes. Res. 6 1988 51S 209S
44. E. Pappadopulos, P.S. Jensen, S.B. Schur, J.C. MacIntyre, S. Ketner, K. Van Orden, J. Sverd, S. Sardana, D. Woodlock, R. Schweitzer, and D. Rube "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings Schizophr. Bull. 28 2002 111 121
45. G. Ratzoni, D. Gothelf, A. Brand-Gothelf, J. Reidman, L. Kikinzon, G. Gal, M. Phillip, A. Apter, and R. Weizman Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study J. Am. Acad. Child Adolesc. Psych. 41 2002 337 343
46. H. Remschmidt Early-onset schizophrenia as a progressive-deteriorating developmental disorder: evidence from child psychiatry J. Neural Transm. 109 2002 101 117
47. H. Remschmidt, C. Fleischhaker, K. Hennighausen, and E. Schulz Management of schizophrenia in children and adolescents. The role of clozapine Paediatr. Drugs 2 2000 253 262
48. M. Ritsner, G. Perelroyzen, H. Ilan, and A. Gibel Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study J. Clin. Psychopharmacol. 24 2004 245 254
49. F.R. Sallee, R. Kurlan, C.G. Goetz, H. Singer, L. Scahill, G. Law, V.M. Dittman, and P.B. Chappell Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study J. Am. Acad. Child Adolesc. Psych. 39 2000 292 299
50. S.C. Schulz, R.L. Findling, L. Friedman, J.T. Kenny, and A.L. Wise Treatment and outcomes in adolescents with schizophrenia J. Clin. Psychiatry 59 Suppl 1 1998 50 54
51. J.A. Shaw, J.E. Lewis, S. Pascal, R.K. Sharma, R.A. Rodriguez, R. Guillen, and M. Pupo-Guillen A study of quetiapine: efficacy and tolerability in psychotic adolescents J. Child Adolesc. Psychopharmacol. 11 2001 415 424
52. E.H. Sholevar, D.A. Baron, and T.L. Hardie Treatment of childhood-onset schizophrenia with olanzapine J. Child Adolesc. Psychopharmacol. 10 2000 69 78
53. L. Sikich, R.M. Hamer, R.A. Bashford, B.B. Sheitman, and J.A. Lieberman A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial Neuropsychopharmacology 29 2003 133 145
54. K.A. Stigler, M.N. Potenza, and C.J. McDougle Tolerability profile of atypical antipsychotics in children and adolescents Paediatr. Drugs 3 2001 927 942
55. S. Tauscher-Wisniewski, S. Kapur, J. Tauscher, C. Jones, Z.J. Daskalakis, G. Papatheodorou, I. Epstein, B.K. Christensen, and R.B. Zipursky Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade J. Clin. Psychiatry 63 2002 992 997
56. K.J. Took, and B.L. Buck The effect on weight of switching from risperidone to quetiapine in children and adolescents who experience excessive weight gain on risperidone Schizophr. Res. 42 2001 248 (suppl)
57. P. Toren, N. Laor, and A. Weizman Use of atypical neuroleptics in child and adolescent psychiatry J. Clin. Psychiatry 59 1998 644 656
58. M. Vanelli, P. Burstein, and J. Cramer Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain Psychiatr. Serv. 52 2001 1248 1250
59. L. Voruganti, L. Cortese, L. Oyewumi, Z. Cernovsky, S. Zirul, and A. Awad Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life Schizophr. Res. 43 2000 135 145
60. E. Walker, and A.M. Bollini Pubertal neurodevelopment and the emergence of psychotic symptoms Schizophr. Res. 54 2002 17 23
61. D. Wiersma, F.J. Nienhuis, C.J. Slooff, and R. Giel Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort Schizophr. Bull. 24 1998 75 85
62. T.E. Wilens, J. Biederman, R.B. Millstein, J. Wozniak, A.L. Hahesy, and T.J. Spencer Risk for substance use disorders in youths with child- and adolescent-onset bipolar disorder J. Am. Acad. Child Adolesc. Psych. 38 1999 680 685